首页> 外文期刊>Ophthalmology >Allogenic limbo-keratoplasty with conjunctivoplasty, mitomycin C, and amniotic membrane for bilateral limbal stem cell deficiency
【24h】

Allogenic limbo-keratoplasty with conjunctivoplasty, mitomycin C, and amniotic membrane for bilateral limbal stem cell deficiency

机译:同种异体角膜移植联合结膜成形术,丝裂霉素C和羊膜治疗双侧角膜缘干细胞缺乏症

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To present the technique and report the results of up to 36 months after allogenic central penetrating limbo-keratoplasty in conjunction with conjunctivoplasty, mitomycin C (MMC), and amniotic membrane (AM) transplantation in patients with bilateral limbal stem cell deficiency (LSCD). Design: Retrospective, consecutive subject cohort study. Participants: Case records of 20 eyes from 20 patients who presented with bilateral LSCD due to aniridia, chemical/thermal burn, cicatrizing pemphigoid, and chronic ocular surface inflammation and who were treated at the University Eye Hospital, Freiburg. Methods: All eyes were treated with central limbo-keratoplasty in conjunction with conjunctivoplasty, MMC, and AM. There were 20 human leukocyte antigen-typed allolimbal transplants from cadaveric donors. All patients received systemic immunosuppression with mycophenolate mofetil or cyclosporine A. Main Outcome Measures: Surgical success was measured by the duration for which a healthy corneal epithelium was maintained. Visual success was measured by an improvement in visual acuity (VA) in the eye during follow-up and directly correlated with central clear graft survival. Results: The follow-up period was up to 34 months (mean, 20 months; median, 22.4 months). Mean VA, measured in decimal fractions, increased from 0.029 (~20/400; median, 0.005; first quartile 0.005; third quartile 0.005) before surgery to 0.281 (20/70; median, 0.2; first quartile 0.04; third quartile 0.55) after surgery. Healthy corneal epithelium showing survival of limbal stem cells was observed in 14 eyes (70%) during complete follow-up. Conclusions: Penetrating limbo-keratoplasty with conjunctivoplasty, MMC, and AM transplantation is a promising new surgical technique for improving vision and conjunctivalization in patients with severe bilateral LSCD necessitating allogenic transplants. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
机译:目的:介绍同种异体中央穿透性角膜缘角膜成形术联合结膜成形术,丝裂霉素C(MMC)和羊膜(AM)移植治疗双侧角膜缘干细胞缺乏症(LSCD)的患者长达36个月的技术并报告结果)。设计:回顾性,连续主题队列研究。参与者:20例患者的20只眼睛的病例记录,这些患者因无虹膜,化学/热灼伤,瘢痕化的类天疱疮和慢性眼表炎症而出现双侧LSCD,并在弗莱堡大学眼科医院接受了治疗。方法:对所有眼睛进行中央角膜缘角膜移植,结膜成形术,MMC和AM联合治疗。有20具来自尸体供体的人白细胞抗原型同种异体移植。所有患者均接受了霉酚酸酯或环孢霉素A的全身性免疫抑制。主要结局指标:手术成功率通过维持健康的角膜上皮持续时间来衡量。视觉成功是通过随访期间眼睛视力(VA)的改善来衡量的,并且与中央透明移植物的存活率直接相关。结果:随访期最长为34个月(平均20个月;中位22.4个月)。手术前的平均VA以十进制分数表示,从0.029(〜20/400;中位数0.005;第一四分位数0.005;第三四分位数0.005)增加到0.281(20/70;中位数0.2;第一四分位数0.04;第三四分位数0.55)手术后。在完整的随访过程中,有14只眼(70%)观察到健康的角膜上皮,显示角膜缘干细胞存活。结论:穿透性角膜移植结合结膜成形术,MMC和AM移植是一种有希望的新手术技术,可改善需要异体移植的严重双侧LSCD患者的视力和结膜形成。财务披露:作者对本文讨论的任何材料均没有所有权或商业利益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号